Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

Mathew Weinstock,[1,2]* Yosra Aljawai,[1]* Elizabeth A. Morgan,[3] Jacob Laubach,[1] Muriel Gannon,[1] Aldo M. Roccaro,[1] Cindy Varga,[1] Constantine S. Mitsiades,[1] Claudia Paba-Prada,[1] Robert Schlossman,[1] Nikhil Munshi,[1] Kenneth C. Anderson,[1] Paul P. Richardson,[1] Edie Weller[1] and Irene M. Ghobrial[1]

[1]Dana-Farber Cancer Institute, Harvard Medical School, [2]Beth Israel Deaconess, Harvard Medical School, and [3]Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Summary

Extramedullary disease (EMD), defined as an infiltrate of clonal plasma cells at an anatomic site distant from the bone marrow, is an uncommon manifestation of multiple myeloma. Six hundred and sixty-three consecutive patients with multiple myeloma who underwent stem cell transplantation between January 2005 and December 2011 were assessed for the presence of EMD. A cohort of 55 patients with biopsy-proven EMD was identified, comprising 8·3% of the total study population. EMD was present at the time of diagnosis in 14·5% of cases and at the time of relapse in 76% of patients. The most common EMD presentations at relapse were liver involvement and pleural effusions. EMD specimens had high expression of CD44 (92%) and moderate expression of CXCR4. The median overall survival from time of myeloma diagnosis was 4·1 years (95% CI: 3·1, 5·1) and the median overall survival from time of EMD diagnosis was 1·3 years (95% CI: 0·8, 2·3). This report demonstrates that the incidence of EMD has not increased with the introduction of novel agents and stem cell transplantation. The most common EMD presentations in the relapsed setting were liver and pleural fluid. The presence of CD44 and CXCR4 expression may represent new markers of EMD that warrant further investigation.

Keywords: multiple myeloma, extramedullary, novel agents, stem cell transplantation, CD44.

Multiple myeloma (MM), a malignancy of terminally differentiated monoclonal plasma cells, continues to afflict a substantial proportion of the population, with an estimated incidence of 21 700 new cases diagnosed per year in the United States (Howlader et al, 2012). Although MM remains incurable, new therapeutic advances over the past 20 years have greatly improved clinical response rates, event-free survival and overall survival in myeloma (Attal et al, 1996; Richardson et al, 2005; Rajkumar et al, 2006; Dimopoulous et al, 2007).

Monoclonal plasma cells, which give rise to the clinical phenotype of MM, most often remain localized to the bone marrow environment. However, there exists a subset of patients with myeloma in whom pathogenic plasma cells can be found at distant anatomical sites, such as the liver, kidney, pleura, breast, testes, skin and meninges, among other tissues. These patients with extramedullary disease (EMD), strictly defined as a clonal plasmacytic infiltrate at an anatomic site distant from the bone marrow or adjacent soft tissue, appear to account for 6–7·5% of the total myeloma population in small series, and tend to have an unfavourable prognosis relative to MM with marrow-only disease (Bartel et al, 2009; Usmani et al, 2012).

At present, there are limited data regarding the basic characteristics of EMD, including incidence, prevalence, clinical characteristics, laboratory features and response to novel therapies. Several previous series investigating EMD have been hampered by definitional inconsistencies, as some authors have deemed EMD to reflect any extension of plasma cells from the marrow to adjacent soft tissues, while others have strictly defined it as the proliferation of plasma cells at anatomical sites physically separated from the bone marrow. For example, in the largest series of EMD to date (Varettoni et al, 2010) EMD was defined as extension from the marrow to the adjacent soft tissues in 85% of cases studied, while in recent analyses, EMD has been defined more narrowly, as evidence of plasma cells at distant locations (Short et al, 2011).

We have previously proposed that EMD should be defined strictly as the presence of an infiltrate of clonal plasma cells at an anatomic site distant from the bone marrow or adjacent soft tissue in a patient with underlying MM (Weinstock & Ghobrial, 2012). Adherence to this definition will aid in the ongoing study of EMD and will permit accurate analysis of this entity's basic epidemiological, clinical, pathogenic, immunophenotypic, cytogenetic and prognostic features.

Here, we report an analysis of EMD incidence, laboratory features and response to therapy among a group of patients with MM who underwent autologous or allogeneic stem cell transplantation at a single, large, academic medical centre in the United States.

Methods

Six-hundred and sixty-three consecutive patients with MM who were treated with either autologous or allogeneic haematopoietic stem cell transplantation at the Dana–Farber Cancer Institute (DFCI) between January 2005 and December 2011 were analysed for the presence or absence of EMD, as well as their laboratory characteristics, specific treatment regimens and response to therapy. Approval for this protocol was obtained from DFCI and was in accordance with the Declaration of Helsinki. All patients were treated with novel therapeutic agents, including thalidomide, lenalidomide or bortezomib. This cohort was chosen in order to most accurately reflect the current state of myeloma therapy, in which novel agents are routinely used in tandem with stem cell transplantation.

The diagnosis of plasma cell neoplasm was rendered on tissue or cytology sections as part of routine clinical care in accordance with the 2008 World Health Organization Classification system. Extramedullary disease relapse was defined as pathological or radiological evidence of EMD at any time following the initial diagnosis of MM. In accordance with the strict definitional criteria noted above, those patients with pathological or radiological evidence of neoplastic plasma cells in the soft tissues adjacent to the axial skeleton, including the epidural space, paraspinal soft tissue and calvarium, were deemed to have locally-advanced myeloma, but not EMD. Patients with plasma cell leukaemia were specifically excluded from this analysis.

Immunohistochemical studies, performed as part of this analysis, utilized the following antibodies: anti-CD138 (Mouse mAb, MI15, Dako, Carpinteria, CA, USA), anti-CXCR4 (Rabbit mAb, UMB2, Abcam, Cambridge, MA, USA), anti-CD56 (Mouse mAb, 123C3, Dako, USA), anti-CD44 (Rat mAb, IM7, eBioscience, San Diego, CA, USA), and anti-CCR6 (Mouse mAb, 53103, R&D Systems, Minneapolis, MN, USA).

Statistical analysis: Patient characteristics were summarized using descriptive statistics. Kaplan–Meier methods were used to estimate survival from the time of myeloma diagnosis and time from EMD diagnosis. We used R version 3·0·2 and the survival package for the analysis (http://www.R-project.org/).

Results

Baseline demographics and characteristics of EMD presentation

Of the entire study cohort of 663 patients who underwent autologous or allogeneic stem cell transplantation for MM at a single, large academic medical centre in the United States between January 2005 and December 2011, 55 were found to have EMD at any time during their disease course (8·3%). The cohort of EMD patients showed a male predominance (63·6%). At the time of MM diagnosis, the cohort of EMD patients had a median haemoglobin of 117 g/l, a median creatinine of 88·4 μmol/l, median calcium of 2·4 mmol/l, median albumin of 39 g/l, median LDH of 183·5 u/l, and median beta-2 microglobulin of 2·79 mg/l (Table I).

The median age at the time of diagnosis of EMD was 52 years (range 34–66). The median haemoglobin was 104 g/l and median LDH elevation was 283·5 u/l at the time of EMD diagnosis. Fifty-three % had immunoglobin G (IgG) heavy chain restriction and 21·8% had immunoglobin A

Table I. Disease characteristics of EMD patients at time of MM diagnosis

Variable	N	%	Reference
Gender			
Male	35	63·6	
Female	20	36·4	
Ig Heavy Chain	55		
A	12	21·8	
G	29	52·7	
n/a	14	25·4	
Ig Light Chain	61		
λ	22	40·0	
κ	33	60·0	
Hb (g/l)	39		
Median		117	
Range		65–151	132–167
Creatinine (μmol/l)	44		
Median		88·4	
Range		44·2–884	61·88–114·92
Calcium (mmol/l)	41		
Median		2·4	
Range		0·925–5	2·2–2·625
Albumin (g/l)	31		
Median		39	
Range		29–50	37–54
LDH (u/l)	20		
Median		183·5	
Range		105–622	107–231
β-2 microglobulin (mg/l)	30		
Median		2·79	
Range		1–20·8	0·2–7

EMD, extramedullary disease; MM, multiple myeloma; Ig, immunoglobulin; Hb, haemoglobin; LDH, lactate dehydrogenase.

(IgA) heavy chain restriction; 40·0% had lambda light chain restriction and 60·0% had kappa light chain restriction.

Extramedullary disease was present at the time of MM diagnosis in 8/55 of these patients (14·5% of all EMD cases). Another 5/55 (9%) patients had EMD at the time of diagnosis and at relapse and 42/55 (76%) patients developed EMD at the time of disease relapse.

The most common locations for EMD at the time of diagnosis of MM were the head and neck soft tissue (31·6%), abdomen (26·3%), chest (21·1%) and central nervous system (12%) (Table II) and included cervical lymph nodes and oropharynx involvement. Involvement in the abdomen included myeloma involvement in the pancreas, peritoneum, kidney and ileum.

The most common locations for EMD at relapse were the abdomen (40%) and the chest (23·9%). The most common sites of involvement were lung and pleural effusions (16%) followed by liver involvement in 15% of the total EMD sites of disease involvement (Table II, Fig 1, 2).

Cytogenetic and molecular characteristics

Cytogenetic analysis of clonal plasma cells in the bone marrow was available for 29/55 (52%) of the patients with EMD at the time of MM diagnosis. Of these, 15/29 had normal cytogenetics (51·7%) and 14/29 had abnormal cytogenetics (48·3%). Hyperdiploidy occurred in 4/14 (28·5%) cases. The most common cytogenetic abnormalities included deletion 13q or monosomy 13 that were present in 9/14 (64%) of cases. *IGH* rearrangements occurred in 6 cases (43%). Two cases (14%) presented with t(11;14), 1q amplification occurred in 1 case (7%) and 17p deletion occurred in 1 case (7%).

Immunohistochemical analysis was available for 11 patients with EMD, and 13 total samples were analysed. These specimens were obtained from various anatomical sites, including the liver, chest wall, abdomen, breast, oral mucosa, pleural fluid, brain and maxillary sinus. Results of immunohistochemical staining confirmed the presence of CD138-positive plasma cells in all examined EMD specimens. Twelve of the 13 EMD biopsy sites were strongly positive for CD44 (92·3%, CI: 86·4–99·6), 5/13 of the EMD biopsy sites were positive for CXCR4 (38·5%, 90% CI: 16·6–64·5) and 5 for CD56 staining (38·5%, 90% CI 16·6–64·5) (Table III, Fig 3).

Therapeutic interventions

The 55 EMD patients were treated with a median of 4 different treatment regimens prior to the development of EMD and a median of 5 total treatment regimens (Table IV). All 55 patients underwent autologous stem cell transplantation and 15 also underwent allogeneic stem cell transplantation (27·3%). The median age at autologous stem cell transplantation was 54·2 years (range 35–69). The most commonly used

combination therapy was dexamethasone/thalidomide (45·5%). Other common regimens included RVD (lenalidomide, bortezomib, dexamethasone; 41·8%), maintenance lenalidomide (36·3%), VD (bortezomib/dexamethasone; 27·3%) and lenalidomide/dexamethasone (25·4%).

Table II. Anatomical location of EMD.

EMD at Diagnosis of MM	N	%	EMD at Relapse	N	%
Total locations (n)	19		Total locations (n)	92	
Head and Neck Soft Tissue	6	31·6	Head and Neck Soft Tissue	12	13·0
Cervical Lymph Node	2	10·5	Orbit	3	3·3
Scalp	1	5·3	Scapula	2	2·2
Lip	1	5·3	Gingiva	2	2·2
Pharynx	1	5·3	Sinus	1	1·1
Tonsil	1	5·3	Cranial Nerve	1	1·1
			Parotid	1	1·1
			Larynx	1	1·1
			Cervical Lymph Node	1	1·1
Central Nervous System	3	15·9	Central Nervous System	13	14·1
Cerebrospinal Fluid	1	5·3	Dura	4	4·3
Spinal Cord	1	5·3	Brain	2	2·2
Brain	1	5·3	Frontal extra-axial mass	2	2·2
			Cerebrospinal Fluid	1	1·1
			Spinal canal	1	1·1
			Leptomeninges	1	1·1
			Thecal	1	1·1
			Subcortical white matter	1	1·1
Chest	4	21·1	Chest	22	23·9
Lung and pleural effusion	4	21·1	Lung & pleural effusion	15	16·3
			Mediastinum	3	3·3
			Breast	2	2·2
			Tracheal arch	1	1·1
			Axillary Lymph Node	1	1·1
Abdomen	5	26·3	Abdomen	40	43·5
Pancreas	1	5·3	Liver	14	15·1
Peritoneum	1	5·3	Peritoneal surface	7	7·5
Kidney	1	5·3	Kidney	6	6·5
Spleen	1	5·3	Mesentery	3	3·2
Ileum	1	5·3	Pancreas	2	2·2
			Spleen	2	2·2
			Para-aortic Lymph Node	1	1·1
			Pelvic Lymph Node	1	1·1
			Ureter	1	1·1
			Iliac Lymph Node	1	1·1
			Buttock	1	1·1
			Paravertebral	1	1·1
Other Soft Tissue	1	5·3	Other Soft Tissue	5	5·4

EMD, extramedullary disease; MM, multiple myeloma

**Fig 1.** Right gluteal soft tissue mass, with biopsy-proven plasma cells.

Fig 2. Positron emission tomography (PET) scan with liver mass demonstrating liver involvement with extramedullary myeloma.

Survival analysis

At a median follow-up from time of MM diagnosis of 8·8 years, 41 patients have died. The median overall survival from time of myeloma diagnosis was 4·1 years, (95% CI: 3·1, 5·1), Fig 4A. The median follow-up time from EMD diagnosis was 4·4 years. The median overall survival from time of EMD diagnosis was 1·3 years (95% CI: 0·8,2·3), Fig 4B.

Discussion

It has been known for many years that EMD portends a worse prognosis relative to marrow-localized MM (Blade *et al*, 1994, 1996). Several characteristic laboratory, cytogenetic and immunophenotypic features of EMD have been identified in small series (Blade *et al*, 2011). However, all studies of EMD that have been published to date have either been small, limited largely to the era prior to the introduction of novel immunomodulatory therapies for MM or have been hampered by inconsistencies in the definition of EMD itself. Our cohort represents a large series of patients with EMD that adheres to a strict definition of biopsy-proven EMD and spans the time of novel therapeutic agents and stem cell transplantation.

Previous series have suggested that EMD may be present in 15–20% of MM cases at the time of diagnosis, and another 15% during the course of their disease (Blade *et al*, 1994, 1996). However, these early studies have been limited to patients with rare and more aggressive MM phenotypes (such as less than 40 years of age at presentation or IgD myeloma), which may be inherently and artificially enriched for a higher proportion of cases of EMD. Other studies of EMD (Varettoni *et al*, 2010) may also overestimate the incidence of EMD because of an overly inclusive definition of this clinical entity.

Our series of EMD patients was selected by using a strict definition of EMD at anatomical sites that were non-contiguous with the bone marrow cavity, and included only those patients with biopsy-proven clonal plasma cell infiltrates. From this series, we determined an EMD incidence of 8·3% among all MM patients. This is consistent with several smaller, recent studies, which indicate an EMD incidence of 6–7·5% at the time of diagnosis (Bartel *et al*, 2009; Short *et al*, 2011).

Other smaller studies have suggested that patients with EMD may share characteristic laboratory features relative to patients with marrow-localized MM, including lower haemoglobin levels, higher LDH levels and increased rates of thrombocytopenia (Barlogie *et al*, 1989; Usmani *et al*, 2012). Our cohort of 55 patients presented with mild anaemia and mildly elevated LDH at the time of MM diagnosis and at the time of EMD development, suggesting that neither the haemoglobin level nor the LDH level is a reliable predictor of MM patients who may already harbour EMD or will proceed to develop EMD during the course of their disease.

Interestingly, the presentation of EMD at the time of diagnosis was mostly in the head and neck area. Lung and pleural effusions as well as abdominal involvement, such as pancreatic or renal involvement, occurred in some cases. However, liver involvement did not occur in any cases at the time of diagnosis. This is in contrast with cases presenting after prior therapeutic interventions. In the relapsed EMD setting, the most common site of

Table III. Immunohistochemical Characteristics of a subset of 11 MM patients with EMD.

Patient	Location	CD138	CXCR4	CD56	CD44	CCR6
1	Liver	POS	NEG	NEG	POS	NEG
1	Chest Wall	POS	NEG	NEG	POS	NEG
2	Liver	POS	NEG	NEG	POS	NEG
3	Liver	POS	POS	NEG	POS	NEG
4	Chest Wall	POS	NEG	POS	POS	NEG
5	Chest Wall	POS	NEG	POS	POS	NEG
6	Abdominal mass	POS	NEG	NEG	POS	NEG
7	Abdominal mass	POS	POS	NEG	POS	NEG
8	Breast	POS	POS	NEG	NEG	NEG
9	Oral mucosa	POS	NEG	POS	POS	NEG
9	Pleural fluid	POS	NEG	POS	POS	NEG
10	Brain	POS	POS	NEG	POS	NEG
11	Maxillary sinus	POS	POS	POS	POS	NEG
Percentage Positive (%)		100	38·46	38·46	92·31	0

EMD, extramedullary disease; MM, multiple myeloma.

Samples from two biopsy sites were analysed for Patients one and nine.

Fig 3. Immunohistochemistry straining of CD138, CD44 and CXCR4 of an extramedullary myeloma sample showing strong positive expression of CD138, CD44 and CXCR4. CD56 and CCR6 were negative in this sample (not shown).

involvement was the liver followed by pleural fluid. These presentations may indicate specific tropism or homing of extramedullary myeloma clones that are more prone to trafficking to these sites. Further investigations into the mechanisms of specific tropism of these aggressive myeloma clones are required. Clinically, attention to liver involvement in patients with myeloma should be considered and routine abdominal imaging may be considered to detect those lesions before significant tumour progression and liver dysfunction occurs.

Table IV. Treatment of patients with EMD.

	N	%	Median
Autologous SCT	55	100	
Allogeneic SCT	15	27·3	
Dexamethasone/Thalidomide	25	45·5	
RVD	23	41·8	
Maintenance Lenalidomide	20	36·3	
Dexamethasone/Bortezomib	15	27·3	
Dexamethasone/Lenalidomide	14	25·4	
Lines of Therapy prior to EMD (n)			4
Total lines of Therapy (n)			5
Age at autologous transplant, years			54·2 (range 35–69)

EMD, extramedullary disease; SCT, stem cell transplantation; RVD, lenalidomide, bortezomib, dexamethasone.

Several bone marrow cytogenetic abnormalities identified in this EMD cohort, particularly deletion of 13q, have been observed in another small, retrospective study of patients with EMD (Rasche *et al*, 2012). Our cytogenetic data were obtained from patients at the time of myeloma diagnosis and not at the time of development of EMD. Cytogenetic or fluorescence *in situ* hybridization studies from the EMD samples or the bone marrow were not available at the time of EMD diagnosis. Given the recent data of clonal evolution and heterogeneity, it would not be surprising to identify specific subclones that have a higher propensity for development of EMD. Therefore, further studies are necessary to refine and differentiate the genomic profile of EMD from that of marrow-localized MM.

The immunophenotypic characteristics of EMD have, as yet, remained poorly defined. A previous small series of seven patients with extramedullary MM reported that CD56, a membrane glycoprotein in the immunoglobulin family, is variably expressed in plasma cells resident in the bone marrow, but is absent in extramedullary plasma cells (Dahl *et al*, 2002). Several reports have therefore suggested that CD56 down-regulation may have a pathogenic role in the development of EMD (Blade *et al*, 2011). In our series, 5 of the 13 analysed EMD specimens (38·5%) were found to be positive for CD56. Although the sample size is small, our findings suggest that CD56 down-regulation may not be as closely linked to EMD pathogenesis as previously described.

Other immunohistochemical studies have reported up-regulation of the cell adhesion molecule CD44 in EMD (Dahl *et al*, 2002). CD44 mediates binding of tumour cells to stroma and regulates interleukin-6 production (Stauder *et al*, 1996). Prior studies have shown variable expression of CD44 with about 73% of the cases showing 20% or more positive expression in one study (Zheng *et al*, 2013). Higher expression was present in patients with recurrent or more aggressive disease. In addition, expression of variant isoforms containing the 9v domain was shown to be associated with an advanced stage and progressive disease with shorter overall survival in MM (Stauder *et al*, 1996).

In our series we confirm that CD44 appears to be reliably over-expressed in EMD specimens (92·3%). However, we did not have matching bone marrow samples for all the EMD samples to compare the relative expression of CD44 in plasma cells present in the bone marrow compared to those present in the EMD sites. Therefore, future studies are required to determine the role of CD44 expression and the different isoforms in the localization of malignant plasma cells in EMD sites.


Fig 4. Survival data. (A) The median overall survival from time of myeloma diagnosis was 4·1 years, (95% confidence interval [CI]: 3·1, 5·1). (B) The median overall survival from time of extramedullary disease (EMD) diagnosis was 1·3 years (95% CI: 0·8,2·3).

.

Additionally, in our series, we note that an increased number of EMD specimens (38·5%) were positive for the presence of CXCR4. This stands in contrast to pre-clinical murine data, in which CXCR4 and other chemokine receptors have been found to be down-regulated in the setting of EMD (Stessman et al, 2013). Further study of the immuno-histochemical characteristics of EMD will be necessary for complete elucidation of the mechanisms that underpin the 'metastatic' transition of marrow-localized MM into EMD.

Previous studies have suggested that the introduction of novel therapeutic agents may have contributed to an increased incidence of EMD over the past two decades (Raanani et al, 2007). However, it is unclear whether this observation is related to improved methods of radiological detection, increased overall survival of the entire MM population in general or greater awareness of EMD as a distinct clinical entity. Our series of cases gathered entirely within the era of routine stem cell transplantation, proteasome inhibition and immunomodulatory therapy, suggests that the incidence of EMD has remained fairly consistent in the time of modern MM therapy.

The survival of the patients in this series remains poor, with a median overall survival of 4·1 years and a median overall survival of 1·3 years from the time of diagnosis of EMD. This indicates an urgent need for the development of better therapeutic modalities that target this unique subset of patients.

In summary, EMD is an uncommon, but by no means rare, manifestation of MM. This cohort of patients 55 patients represents a large group of patients with EMD who were treated in the era of novel therapeutic strategies and autologous or allogeneic haematopoietic stem cell transplantation for MM at a single academic medical centre. The presence of surface markers of CXCR4 and CD44 may represent new biological markers for EMD but need further confirmation. Further study of these patients' molecular characteristics and responses to therapy will be necessary so that this distinct disease entity can continue to be characterized.

Acknowledgements

Author contribution

Mathew Weinstock: performed the research, designed the research, analysed the data and wrote the paper. Yosra Aljawai: performed the research, designed the research, analysed the data and wrote the paper. Elizabeth A. Morgan: performed the research, analysed the data and wrote the paper. Jacob Laubach: designed the research and wrote the paper. Muriel Gannon: performed the research. Aldo M. Roccaro: designed the research and analysed the data. Cindy Varga: performed the research. Constantine S. Mitsiades: analysed the data and wrote the paper. Claudia Paba-Prada: analysed the data and wrote the paper. Robert Schlossman: analysed the data and wrote the paper. Nikhil Munshi: analysed the data and wrote the paper. Kenneth C. Anderson: analysed the data and wrote the paper. Paul P. Richardson: analysed the data and wrote the paper. Edie Weller: analysed the data and wrote the paper. Irene M. Ghobrial: performed the research, designed the research, analysed the data and wrote the paper.

Competing interests

The authors have no competing interests.

References

Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91–97.

Barlogie, B., Smallwood, L., Smith, T. & Alexanian, R. (1989) High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Annals of Internal Medicine, 110, 521–525.

Bartel, T.B., Haessler, J., Brown, T.L., Shaughnessy, Jr, J.D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J. & Barlogie, B. (2009) F-18 fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114, 2068–2076.

Blade, J., Lust, J.A. & Kyle, R.A. (1994) Immuglobulin D multiple myeloma: presenting features, reponse to therapy, and survival in a series of 53 cases. Journal of Clinical Oncology, 12, 2398–2404.

Blade, J., Kyle, R.A. & Greipp, P.R. (1996) Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. British Journal of Haematology, 93, 345–351.

Blade, J., Fernandez de Larrea, C., Rosinol, L., Cibeira, M.T., Jimenez, R. & Powles, R. (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology, 29, 3805–3812.

Dahl, I.M., Rasmussen, T., Kauric, G. & Husebekk, A. (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. British Journal of Haematology, 116, 273–277.

Dimopoulous, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123–2132.

Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J. & Cronin, K.A. (eds) (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on Novemner 2011 SEER data submission, posted to the SEER website, 2012. Accessed 1 November 2014.

Raanani, P., Shpilberg, O. & Ben-Bassat, I. (2007) Extramedullary disease and targeted therapies

for hematologic malignancies—is the association real? *Annals of Oncology*, **18**, 7–12.

Rajkumar, S.V., Blood, E., Vessole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. *Journal of Clinical Oncology*, **24**, 431–436.

Rasche, L., Bernard, C., Topp, M., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H. & Knop, S. (2012) Features of extramedulllary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. *Annals of Hematology*, **91**, 1031–1037.

Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezo-

mib or high-dose dexamethasone for relapsed multiple myeloma. *New England Journal of Medicine*, **352**, 2487–2498.

Short, K.D., Rajkumar, S.V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V., Kyle, R.A. & Lacy, M.Q. (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of Pomalidomide on extramedullary myeloma. *Leukemia*, **25**, 906–908.

Stauder, R., Van Driel, M., Schwärzler, C., Thaler, J., Lokhorst, H.M., Kreuser, E.D., Bloem, A.C., Günthert, U. & Eisterer, W. (1996) Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. *Blood*, **88**, 3101–3108.

Stessman, H.A., Mansoor, A., Zhan, F., Janz, S., Linden, M.A., Baughn, L.B. & Van Ness, B. (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. *Leukemia*, **27**, 2075–2077.

Usmani, S.Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., Van Rhee, F., Crowley, J. & Barlogie, B. (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is overrepresented in high risk disease even in the era of novel agents. *Haematologica*, **97**, 1761–1767.

Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. & Lazzarino, M. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. *Annals of Oncology*, **21**, 325–330.

Weinstock, M. & Ghobrial, I.M. (2012) Extramedullary multiple myeloma. *Leukemia and Lymphoma*, **54**, 1135–1141.

Zheng, W., Liu, D., Fan, X., Powers, L., Goswami, M., Hu, Y., Lin, P., Medeiros, L.J. & Wang, S.A. (2013) Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. *Cytometry B Clin Cytom*. **4**:222–228.